Facial filler is out, fat grafting is in. Read more in this week’s WSJ Wellness newsletter.

The popularity of GLP-1s is shifting facial aesthetic trends. Plus, a fast-food chain that’s gone full…

A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study

The Phase 3 study found a drug didn’t reduce the risk of cardiovascular events like heart…

Hundreds of Colleges Are Sending Acceptance Letters to Kids Who Didn’t Even Apply

Amid shrinking enrollment, more schools are offering direct admissions. “Instead of a student applying to the…

Mamdani’s Chief Antagonist Is a Litigator Who Stared Down the Mob

Lawyer and former public servant Randy Mastro has filed lawsuits challenging the mayor’s pied-Ă -terre tax rollout…

Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research

Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising…

The Ex-Salesman Who Serves Up Far-Right Policies With a Smile

A 35-year-old candidate with folksy appeal has become the new face of Germany’s AfD party.

Watch Dr. Ben Bassin break down the lifesaving secrets behind hospital design, from swapping beds for chairs to a Disney-inspired ward layout

Watch Dr. Ben Bassin redesign an emergency department to make it less chaotic.

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Novartis shares rose after the drugmaker reported positive results in two late-stage trials from its new…

Swiss drugmaker Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders, after three patients died

Novartis halted eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late…

Health Care Roundup: Market Talk

Gain insight on Novartis, Bangkok Chain Hospital and more in the latest Market Talks covering the…